1. Home
  2. HSPO vs HLVX Comparison

HSPO vs HLVX Comparison

Compare HSPO & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • HLVX
  • Stock Information
  • Founded
  • HSPO 2014
  • HLVX 2020
  • Country
  • HSPO United States
  • HLVX United States
  • Employees
  • HSPO N/A
  • HLVX N/A
  • Industry
  • HSPO Blank Checks
  • HLVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • HLVX Health Care
  • Exchange
  • HSPO Nasdaq
  • HLVX Nasdaq
  • Market Cap
  • HSPO 92.0M
  • HLVX 88.7M
  • IPO Year
  • HSPO 2022
  • HLVX 2022
  • Fundamental
  • Price
  • HSPO $11.66
  • HLVX $1.73
  • Analyst Decision
  • HSPO
  • HLVX Hold
  • Analyst Count
  • HSPO 0
  • HLVX 5
  • Target Price
  • HSPO N/A
  • HLVX $2.33
  • AVG Volume (30 Days)
  • HSPO 878.0
  • HLVX 139.8K
  • Earning Date
  • HSPO 01-01-0001
  • HLVX 05-08-2025
  • Dividend Yield
  • HSPO N/A
  • HLVX N/A
  • EPS Growth
  • HSPO 2.63
  • HLVX N/A
  • EPS
  • HSPO 0.28
  • HLVX N/A
  • Revenue
  • HSPO N/A
  • HLVX N/A
  • Revenue This Year
  • HSPO N/A
  • HLVX N/A
  • Revenue Next Year
  • HSPO N/A
  • HLVX N/A
  • P/E Ratio
  • HSPO $41.39
  • HLVX N/A
  • Revenue Growth
  • HSPO N/A
  • HLVX N/A
  • 52 Week Low
  • HSPO $10.84
  • HLVX $1.55
  • 52 Week High
  • HSPO $12.41
  • HLVX $18.24
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 48.28
  • HLVX 37.55
  • Support Level
  • HSPO $11.61
  • HLVX $1.78
  • Resistance Level
  • HSPO $11.74
  • HLVX $1.91
  • Average True Range (ATR)
  • HSPO 0.01
  • HLVX 0.06
  • MACD
  • HSPO -0.00
  • HLVX -0.00
  • Stochastic Oscillator
  • HSPO 38.46
  • HLVX 5.26

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About HLVX HilleVax Inc.

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Share on Social Networks: